Phase III Multicenter Study of the Effects on Quality of Life of Three-weekly Versus Weekly First-line Chemotherapy for Metastatic or Locally Advanced Breast Cancer
Patients with locally advanced breast cancer and patients with metastatic breast cancer who
have not previously received an anthracycline will be treated with docetaxel and epirubicin.
Patients with metastatic breast cancer who have already received anthracyclines will be
treated with docetaxel and capecitabine.
All patients will be randomized to receive their treatment either on an every three week
schedule, or on a weekly schedule.
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
quality of life
during first 6 weeks of chemotherapy
Andrea de Matteis, M.D.
NCI Naples, Division of Medical Oncology C
Italy: Ethics Committee